Travere Therapeutics (TVTX) Non-Current Debt (2014 - 2015)

Travere Therapeutics (TVTX) reported Non-Current Debt of $40.8 million for Q1 2015, up 1.6% quarter-over-quarter from $40.2 million in Q3 2014.

Travere Therapeutics (TVTX) Non-Current Debt (2014 - 2015) Analysis & Trends

Travere Therapeutics has reported Non-Current Debt for 2 years, with the latest figure at $40.8 million in Q1 2015.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	319.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Travere Therapeutics	5.07 Bn	4.99 Bn	102.38 Mn	-

Download Data